ライフサイエンスコーパス: phosphokinase

1 oligomycin A, phosphocreatine, and creatine phosphokinase.

2 sessed by measuring the levels of creatinine phosphokinase.

3 doxin, ovalbumin, and rabbit muscle creatine phosphokinase.

4 entified as regulators of phospholipases and phosphokinases.

5 tion in either group were increased creatine phosphokinase (52 [19%] of 269 patients in the binimetin

6 tionally rewired via cAMP and cAMP-dependent phosphokinase A (PKA)-mediated activation of the cAMP-re

7 inc supplementation decreased serum creatine phosphokinase activities and eliminated the difference b

8 Serum creatine phosphokinase activity was significantly higher in the a

9 protein has constitutively elevated tyrosine phosphokinase activity.

10 changes, and the increase in serum creatine phosphokinase activity.

11 se factors, which lacked detectable creatine phosphokinase and ATPase activities, creatine phosphate

12 nduced increases in the activity of creatine phosphokinase and creatine kinase-MB.

13 ced an elevation in serum levels of creatine phosphokinase and myocardial injury characterized by the

14 Phosphokinases and protein tyrosine phosphorylation were

15 abeling, (iii) a reduction in serum creatine phosphokinase, and (iv) improved weight gain.

16 id peroxidation, elevation of serum creatine phosphokinase, and functional changes in the isolated at

17 ase duration, skin score, levels of creatine phosphokinase, and presence of tendon friction rubs.

18 count and electrolyte, creatinine, creatine phosphokinase, and troponin T levels were normal.

19 ion and role was examined by immunostaining, phosphokinase antibody arrays, Western blot analysis, an

20 pip92/Ier2/ETR101 does not appear to require phosphokinase C activity for transcriptional activation.

21 Also, mTOR-regulated phosphokinase C epsilon (PKCe) activity induced phosphor

22 Additionally, in 9 pigs, creatine phosphokinase (CK) activity in embolized myocardium was

23 3Gly (rs11559024) with constitutive creatine phosphokinase (CK) levels, CK variation, and inducibilit

24 an asymptomatic increase in plasma creatine phosphokinase concentration (200 mg, n=5; 400 mg, n=3; 8

25 n, ADP scavenger creatine phosphate/creative phosphokinase (CP/CPK), and ARL-66096, an antagonist of

26 sient increase in the muscle enzyme creatine phosphokinase (CPK) 4 weeks after gene transfer.

27 on muscle cells and the release of creatine phosphokinase (CPK) as a sequela of that deficiency.

28 e to microbiological clearance, and creatine phosphokinase (CPK) elevation.

29 d eosinophilia and elevated serum creatinine phosphokinase (CPK) levels were observed beginning durin

30 , triglyceride, liver enzyme, and creatinine phosphokinase (CPK) levels; weight; and Brief Pain Inven

31 Serial creatine phosphokinase (CPK)-MB levels were determined after elec

32 lactate dehydrogenase (LDH), and creatinine phosphokinase (CPK).

33 .1.3); (ii) transferase activity of creatine phosphokinase (EC 2.7.3.2) and hexokinase (EC 2.7.1.1);

34 nt-related adverse events occurred (creatine phosphokinase elevation attributed to antilipid therapy

35 d included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite.

36 No cases of creatine phosphokinase elevations > or =10 times upper limit of n

37 t is associated with moderate serum creatine phosphokinase elevations in up to 12% of patients.

38 tatin and 7 placebo patients due to creatine phosphokinase elevations; no cases of mild or severe myo

39 Proteasome proteolytic activities and phosphokinase expression were assessed by using specific

40 atient at 20 mg/kg, increased blood creatine phosphokinase in two patients at 20 mg/kg, and increased

41 acebo and vemurafenib group), blood creatine phosphokinase increase (30 [12%] vs one [<1%]), and alan

42 Grade 4 toxicities included creatinine phosphokinase increase (four patients), arterial injury

43 lymphopenia in two patients, blood creatine phosphokinase increase in one patient, aminotransferase

44 ssociation of elevated troponin and creatine phosphokinase isoenzyme levels with mortality and organ

45 ffects on extrarenal injury (plasma creatine phosphokinase, lactate dehydrogenase, and hematocrit lev

46 ps (all p > 0.05), whereas the peak creatine phosphokinase level was significantly reduced in group 2

47 vity Score (DAS) for juvenile DM, creatinine phosphokinase level, aldolase level, absolute number of

48 Elevated temperature, an elevated creatine phosphokinase level, and autonomic dysfunction led to co

49 wer ejection fractions, higher peak creatine phosphokinase levels (P < .0001), and more diseased vess

50 ecipients tested had elevated serum creatine phosphokinase levels and detectable serum myoglobin.

51 t prominent in patients with peak creatinine phosphokinase levels between 500 and 1,000 mg/dl (86% vs

52 Examination of serum creatine phosphokinase levels in these mice revealed significant

53 Creatinine phosphokinase, liver enzyme serum levels, and renal func

54 Creatine phosphokinase-MB bands, troponin levels, and pulmonary w

55 opment of new pathologic Q waves or creatine phosphokinase-MB isoenzyme elevation >8 x upper limits o

56 scle, leading to decreased myosin creatinine phosphokinase (MCK) expression and binding activities.

57 ipts including muscle mitochondrial creatine phosphokinase, muscle glycogen phosphorylase, hexokinase

58 Creatinine phosphokinase myocardial band fractions were not signifi

59 une disorder (n=3), increased blood creatine phosphokinase (n=2), and increased aspartate aminotransf

60 inine phosphokinase, r = 0.76 for creatinine phosphokinase of the muscle band, and r = 0.75 for tropo

61 treatment group B), increased blood creatine phosphokinase (one [1%] vs four [4%]), and hypophosphata

62 e, diabetes, smoking history, serum creatine phosphokinase, or electrocardiographic findings.

63 ize (p < 0.001), cardiac release of creatine phosphokinase (p < 0.001), and apoptotic cell death (p <

64 ibrate, but not LY518674, increased creatine phosphokinase (P = .004 vs placebo).

65 were found to contain casein kinase (CK) 2, phosphokinase (PK)C phosphorylation, and N-myristoylatio

66 ng multidetector CT (r = 0.82 for creatinine phosphokinase, r = 0.76 for creatinine phosphokinase of

67 h in myocardial damage, assessed by creatine phosphokinase release, and in endothelial cell and cardi

68 oved cardiac function and decreased creatine phosphokinase release.

69 oved cardiac function and decreased creatine phosphokinase release.

70 ssment of lactate dehydrogenase and creatine phosphokinase release.

71 On the basis of the results of phosphokinase screening arrays, we here investigate the

72 had eye defects or elevated muscle creatine phosphokinase, separating the TMTC3 COB phenotype from t

73 y values, including increased blood creatine phosphokinase (seven [8%]), increased alanine aminotrans

74 ork that traverses AP-1-activating and other phosphokinase signaling cascades.

75 re were no significant changes in creatinine phosphokinase, trough cyclosporine levels, or total cycl

76 Creatine phosphokinase values were monitored and increased above

77 y, skin score, serum creatinine and creatine phosphokinase values, hypothyroidism, and cardiac involv

78 ared to be normal with exception of creatine phosphokinase, which peaked at 7 days after infection.